{
  "id": 20671523,
  "title": "Mesoblast at Bell Potter Healthcare Conference: pipeline, sales and filings",
  "url": "https://urgent.news/2026/11/18/mesoblast-at-bell-potter-healthcare-conference-pipeline-sales-and",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T23:11:19.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/mesoblast-at-bell-potter-healthcare-conference-pipeline-sales-and-filings-93CH-5037327"
  },
  "original_language": "en",
  "account": null,
  "summary": "Mesoblast Limited (MESO) used the Bell Potter Healthcare Conference to present a year of commercial progress and discuss its pipeline, which could bring several regulatory and clinical catalysts in the coming year. The company reported fiscal 2026 net revenues of $115 million and gross profit, excluding amortization, of $110 million. RYONCIL, Mesoblast's FDA-approved allogeneic stem cell therapy, completed its first year of commercialization with more than 98% commercial insurance coverage and over 50 treatment centers onboarded. The company also completed treatment of 350 patients in its Phase III chronic low back pain trial, with a primary endpoint readout expected in mid-2027. Mesoblast secured a $125 million five-year non-dilutive credit facility to consolidate and retire two higher-cost facilities, improving its debt structure while preserving cash for development work.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}